Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00280_DB00582_nanopub.RACPtPUrUgghnOp5v_fIx9kMVYXjjgx0ZwQI8rqxtz72Y#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00280_DB00582 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00280_DB00582 label "DDI between Disopyramide and Voriconazole - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed. [drugbank_resource:DB00280_DB00582]" assertion.
- drugbank_resource:DB00280_DB00582 identifier "drugbank_resource:DB00280_DB00582" assertion.
- drugbank_resource:DB00280_DB00582 title "DDI between Disopyramide and Voriconazole - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed." assertion.
- drugbank:DB00280 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00280_DB00582 assertion.
- drugbank:DB00582 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00280_DB00582 assertion.